8 months ago
JNJ
AnalystsAsad HaiderAsad Haider's Stock Forecasts
AnalystsAsad Haider
Sectors:
Industries:
Analyst Ranking
Top 42%
#2135 out of 5156 analysts
Average Return
+18.3%
Win Rate
80%4 out of 5
Risk vs Reward
Poor
Good
Asad Haider's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Eli Lilly & CoLLY | +45.53% | $726.24 | $1,056.88 | 2025-04-07 - 2025-12-18 | Strong Buy |
Johnson & JohnsonJNJ | +37.98% | $150.97 | $208.31 | 2025-04-08 - 2025-12-18 | Strong Buy |
Johnson & JohnsonJNJ | +9.02% | $191.08 | $208.31 | 2025-10-08 - 2025-12-18 | Strong Buy |
Royalty Pharma PLCRPRX | +8.93% | $35.28 | $38.43 | 2025-09-29 - 2025-12-18 | Strong Buy |
Asad Haider Analyst Color
Get additional color on Asad Haider's coverage of popular stocks
8 months ago
LLY
8 months ago
PFE
Asad Haider's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Newamsterdam Pharma Co NvNAMS | 2 | Hold | $37.00 | +9.14% | Maintains | 17 days ago |
Bristol Myers Squibb CoBMY | 2 | Hold | $57.00 | +6.88% | Maintains | 17 days ago |
Johnson & JohnsonJNJ | 2 | Strong Buy | $212.00 | +1.77% | Maintains | 2 months ago |
Innoviva IncINVA | 1 | Strong Sell | $17.00 | -15.30% | Initiates Coverage On | 3 months ago |
Royalty Pharma PLCRPRX | 1 | Strong Buy | $42.00 | +9.29% | Initiates Coverage On | 3 months ago |
Vaxcyte IncPCVX | 1 | Hold | $38.00 | -13.06% | Initiates Coverage On | 3 months ago |
Biontech SeBNTX | 1 | Hold | $110.00 | +20.27% | Initiates Coverage On | 7 months ago |
Eli Lilly & CoLLY | 1 | Strong Buy | $888.00 | -15.98% | Upgrades | 8 months ago |
Abbvie IncABBV | 1 | Hold | $194.00 | -12.93% | Assumes | 8 months ago |
Pfizer IncPFE | 1 | Hold | $25.00 | -0.16% | Downgrades | 8 months ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.